Taeseong Jeong

Taeseong Jeong

orcid

Research Focus & Metrics

Representative Publications

View All Publications
31 March 2022 in Journal of Pharmacopuncture
Verified
Journal Article
Open access
PDF file
HJHoseok Jung
Hoseok Jung
WSWOOKCHEOL SEO
WOOKCHEOL SEO
TJTaeseong Jeong
Taeseong Jeong
HKHyung Won Kang
Hyung Won Kang
SKSungchul Kim
Sungchul Kim
Hoseok Jung, Wookcheol Seo, Taeseong Jeong, Hyung Won Kang, Sungchul Kim. J Pharmacopuncture 2022;25:46-51. https://doi.org/10.3831/KPI.2022.25.1.46

31 May 2024 in Journal of Acupuncture Research
Verified
Journal Article
Open access
PDF file
TJTaeseong Jeong
Taeseong Jeong
ECEunbyul Cho
Eunbyul Cho
SKSungha Kim
Sungha Kim
SOSeunghyun Oh
Seunghyun Oh
SKSuhak Kim
Suhak Kim
SKSungchul Kim
Sungchul Kim
Taeseong Jeong, Eunbyul Cho, Sungha Kim, Seunghyun Oh, Suhak Kim, Jeongsu Park, Sungchul Kim. Journal of Acupuncture Research 2024;41:135-41. https://doi.org/10.13045/jar.24.0004

19 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
SJShin Joonyoung
Shin Joonyoung
HLHyorin Lee
Hyorin Lee
TJTaeseong Jeong
Taeseong Jeong
ECEunhye Cha
Eunhye Cha
WSWOOKCHEOL SEO
WOOKCHEOL SEO
SKSungchul Kim
Sungchul Kim
Background/Objectives: Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by progressive muscle weakness and paralysis, with respiratory failure being the leading cause of death. Mecasin (KCHO-1), a standardized botanical extract, has demonstrated neuroprotective and anti-neuroinflammatory effects in preclinical studies. A 12-week phase IIa trial suggested a potential benefit in slowing functional decline. This phase IIb trial evaluated the efficacy and safety of Mecasin over 24 weeks, including respiratory-related outcomes. Methods: In this multicenter, randomized, double-blind, placebo-controlled trial, 50 patients were randomized to receive Mecasin (2.4 g/day) or placebo for 24 weeks, with both groups receiving riluzole (100 mg/day). Forty-three patients were included in the efficacy analysis. The primary endpoint was change in the Korean version of the ALS Functional Rating Scale-Revised (K-ALSFRS-R) total score. Respiratory-related assessments included orthopnea, FEV1/FVC, and end-tidal CO2, alongside safety evaluations. Results: At week 24, K-ALSFRS-R changes were −3.65 and −3.74 points in the Mecasin and placebo groups, respectively, with no significant between-group difference (estimated difference, 0.27; 90% CI, −1.80 to 2.33; p = 0.4146). Significant between-group differences were observed in FEV1/FVC (7.69 percentage points; p = 0.0036) and end-tidal CO2 (−3.92 mmHg; p = 0.0076). Linear mixed-effects models showed significant group-by-visit interactions for orthopnea (p = 0.0212) and FEV1/FVC (p = 0.0228). Adverse-event frequencies were comparable. Conclusions: Although Mecasin did not show a significant effect on the primary outcome (K-ALSFRS-R total score), the observed differences in respiratory-related outcomes provide a clinical rationale for further investigation in larger trials focusing on respiratory function.